Executive Roundtable:
Make Your
CRO
A True
Extension Of Your
Internal Team
By Rob Wright
In May 2011, Pfizer announced it would reduce its
clinical research functional service providers from 17
to 2. Initially, this 88% reduction seemed to contradict the trend of pharma and biopharma to increasingly outsource clinical research. That year, the global
healthcare contract research outsourcing market was
valued at $25.1 billion. By 2018, the market is forecast
to reach $65 billion. How can the clinical research
market be growing, when companies like Pfizer are
employing fewer organizations? Simple. The move
on the part of Pfizer is representative of the growing
trend of strategic partnering ��� putting more of your
research eggs into fewer CRO research baskets.
ROUNDTABLE
PARTICIPANTS
Dr. Kenneth Burhop,
chief scientific officer,
Sangart
Carolyn Green,
president and director,
Atreaon
Jim Hauske,
president and founder,
Sensor Pharmaceuticals
John Hubbard, senior VP
and worldwide head of
development operations,
Pfizer
Mitch Katz,
executive director of
medical research operations,
Purdue Pharma
Mary Rose Keller,
VP of clinical operations,
Sangart
Thomas Wessel, M.D., Ph.D,
consultant and former CMO,
Acorda Therapeutics, Inc.
Leslie Williams,
president, CEO,
and founder,
ImmusanT
The CRO Leadership Awards 2013
7